Conditions: Healthy Volunteers
Keywords: Mild Cognitive Impairment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 30
Healthy volunteers: yes

Brief summary:
The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body.

Detailed description:

Arms:
arm 1: Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days arm 2: QD oral dosing for 14 consecutive days arm 3: Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days arm 4: Single oral dose

Interventions: intervention 1: LY2886721 intervention 2: Placebo
Intervention descriptions: intervention 1: Administered orally. intervention 2: Administered orally.

Protocol document: